BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fernández-Montero JV, Barreiro P, de Mendoza C, Labarga P, Soriano V. Hepatitis C virus coinfection independently increases the risk of cardiovascular disease in HIV-positive patients. J Viral Hepat. 2016;23:47-52. [PMID: 26390144 DOI: 10.1111/jvh.12447] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 6.3] [Reference Citation Analysis]
Number Citing Articles
1 Nou E, Lo J, Grinspoon SK. Inflammation, immune activation, and cardiovascular disease in HIV. AIDS 2016;30:1495-509. [PMID: 27058351 DOI: 10.1097/QAD.0000000000001109] [Cited by in Crossref: 104] [Cited by in F6Publishing: 61] [Article Influence: 17.3] [Reference Citation Analysis]
2 Lledó G, Benítez-Gutiérrez L, Arias A, Requena S, Cuervas-Mons V, de Mendoza C. Benefits of hepatitis C cure with antivirals: why test and treat? Future Microbiol 2019;14:425-35. [PMID: 30900911 DOI: 10.2217/fmb-2019-0041] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Jillella DV, Wisco DR. Infectious causes of stroke. Curr Opin Infect Dis 2019;32:285-92. [PMID: 30973394 DOI: 10.1097/QCO.0000000000000547] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 7.5] [Reference Citation Analysis]
4 Roca B, Mendoza MA, Roca M. Within subject variability of HDL-cholesterol in HIV-infected patients. Postgrad Med 2020;132:162-6. [PMID: 31575314 DOI: 10.1080/00325481.2019.1675329] [Reference Citation Analysis]
5 Leidner AJ, Chesson HW, Spradling PR, Holmberg SD. Assessing the Effect of Potential Reductions in Non-Hepatic Mortality on the Estimated Cost-Effectiveness of Hepatitis C Treatment in Early Stages of Liver Disease. Appl Health Econ Health Policy 2017;15:65-74. [PMID: 27480538 DOI: 10.1007/s40258-016-0261-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
6 Townsend K, Meissner EG, Sidharthan S, Sampson M, Remaley AT, Tang L, Kohli A, Osinusi A, Masur H, Kottilil S. Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration. AIDS Res Hum Retroviruses 2016;32:456-62. [PMID: 26559180 DOI: 10.1089/AID.2015.0170] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
7 Sherman KE, Kang M, Sterling R, Umbleja T, Marks K, Kiser JJ, Alston-Smith B, Greaves W, Butt AA, the ACTG 5294 BIRTH Study Team. Phase 3 trial of first generation protease inhibitor therapy for hepatitis C virus/human immunodeficiency virus coinfection. World J Hepatol 2017; 9(4): 217-223 [PMID: 28217259 DOI: 10.4254/wjh.v9.i4.217] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
8 Osibogun O, Ogunmoroti O, Michos ED, Spatz ES, Olubajo B, Nasir K, Madhivanan P, Maziak W. HIV/HCV coinfection and the risk of cardiovascular disease: A meta-analysis. J Viral Hepat. 2017;24:998-1004. [PMID: 28502092 DOI: 10.1111/jvh.12725] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 4.6] [Reference Citation Analysis]
9 Tan BK, Chalouni M, Ceron DS, Cinaud A, Esterle L, Loko MA, Katlama C, Poizot-Martin I, Neau D, Chas J, Morlat P, Rosenthal E, Lacombe K, Naqvi A, Barange K, Bouchaud O, Gervais A, Lascoux-Combe C, Garipuy D, Alric L, Goujard C, Miailhes P, Aumaitre H, Duvivier C, Simon A, Lopez-Zaragoza JL, Zucman D, Raffi F, Lazaro E, Rey D, Piroth L, Boué F, Gilbert C, Bani-Sadr F, Dabis F, Sogni' P, Wittkop L, Boccara F; ANRS CO13 HEPAVIH study group. Atherosclerotic Cardiovascular Events in Patients Infected With Human Immunodeficiency Virus and Hepatitis C Virus. Clin Infect Dis 2021;72:e215-23. [PMID: 32686834 DOI: 10.1093/cid/ciaa1014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 De Pablo-Bernal RS, Jimenez-Leon MR, Tarancon-Diez L, Gutierrez-Valencia A, Serna-Gallego A, Trujillo-Rodriguez M, Alvarez-Rios AI, Milanes-Guisado Y, Espinosa N, Roca-Oporto C, Viciana P, Lopez-Cortes LF, Ruiz-Mateos E. Modulation of Monocyte Activation and Function during Direct Antiviral Agent Treatment in Patients Coinfected with HIV and Hepatitis C Virus. Antimicrob Agents Chemother 2020;64:e00773-20. [PMID: 32571815 DOI: 10.1128/AAC.00773-20] [Reference Citation Analysis]
11 Goossens N, Negro F. Cardiovascular Manifestations of Hepatitis C Virus. Clin Liver Dis 2017;21:465-73. [PMID: 28689586 DOI: 10.1016/j.cld.2017.03.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
12 Maggi P, Bruno G, Perilli F, Saracino A, Volpe A, Santoro C, Ladisa N, Angarano G. Effects of Therapy with Maraviroc on the Carotid Intima Media Thickness in HIV-1/HCV Co-infected Patients. In Vivo 2017;31:125-31. [PMID: 28064231 DOI: 10.21873/invivo.11035] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
13 Crane HM, Nance RM, Avoundjian T, Harding BN, Whitney BM, Chow FC, Becker KJ, Marra CM, Zunt JR, Ho EL, Kalani R, Huffer A, Burkholder GA, Willig AL, Moore RD, Mathews WC, Eron JJ, Napravnik S, Lober WB, Barnes GS, Mcreynolds J, Feinstein MJ, Heckbert SR, Saag MS, Kitahata MM, Delaney JA, Tirschwell DL. Types of Stroke Among People Living With HIV in the United States. JAIDS Journal of Acquired Immune Deficiency Syndromes 2021;86:568-78. [DOI: 10.1097/qai.0000000000002598] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Bonfiglio CA, Weber C, Atzler D, Lutgens E. Immunotherapy and cardiovascular diseases (CVD): novel avenues for immunotherapeutic approaches. QJM 2021:hcab207. [PMID: 34293177 DOI: 10.1093/qjmed/hcab207] [Reference Citation Analysis]
15 Mondal P, Aljizeeri A, Small G, Malhotra S, Harikrishnan P, Affandi JS, Buechel RR, Dwivedi G, Al-Mallah MH, Jain D. Coronary artery disease in patients with human immunodeficiency virus infection. J Nucl Cardiol 2021;28:510-30. [PMID: 32820424 DOI: 10.1007/s12350-020-02280-4] [Reference Citation Analysis]
16 Bhatia NS, Chow FC. Neurologic Complications in Treated HIV-1 Infection. Curr Neurol Neurosci Rep 2016;16:62. [PMID: 27170369 DOI: 10.1007/s11910-016-0666-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
17 Bedimo R, Abodunde O. Metabolic and Cardiovascular Complications in HIV/HCV-Co-infected Patients. Curr HIV/AIDS Rep. 2016;13:328-339. [PMID: 27595755 DOI: 10.1007/s11904-016-0333-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
18 Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC, Sperling L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082-e1143. [PMID: 30586774 DOI: 10.1161/cir.0000000000000625] [Cited by in Crossref: 250] [Cited by in F6Publishing: 310] [Article Influence: 62.5] [Reference Citation Analysis]
19 Farmakiotis D, Weiss Z, Brotherton AL, Morrissey P, Gohh R, Vieira K, Taylor LE, Garland JM. Successful Kidney Transplantation in a Recipient Coinfected with Hepatitis C Genotype 2 and HIV from a Donor Infected with Hepatitis C Genotype 1 in the Direct-Acting Antiviral Era. Case Reports Hepatol 2020;2020:7679147. [PMID: 32082657 DOI: 10.1155/2020/7679147] [Reference Citation Analysis]
20 Kase K, Avi R, Toompere K, Rajasaar H, Pauskar M, Soodla P, Jõgeda EL, Zilmer K, Lutsar I, Huik K. Dynamics of hepatitis C epidemic among people living with HIV in Estonia based on Estonian HIV cohort study. BMC Infect Dis 2021;21:792. [PMID: 34376170 DOI: 10.1186/s12879-021-06521-w] [Reference Citation Analysis]
21 Vinhaes CL, Araujo-Pereira M, Tibúrcio R, Cubillos-Angulo JM, Demitto FO, Akrami KM, Andrade BB. Systemic Inflammation Associated with Immune Reconstitution Inflammatory Syndrome in Persons Living with HIV. Life (Basel) 2021;11:65. [PMID: 33477581 DOI: 10.3390/life11010065] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Butt ZA, Shrestha N, Gesink D, Murti M, Buxton JA, Gilbert M, Balshaw RF, Wong S, Kuo M, Wong J, Yu A, Alvarez M, Samji H, Roth D, Consolacion T, Hull MW, Ogilvie G, Tyndall MW, Krajden M, Janjua NZ. Effect of opioid-substitution therapy and mental health counseling on HIV risk among hepatitis C-infected individuals. Clin Epidemiol 2018;10:1127-45. [PMID: 30214316 DOI: 10.2147/CLEP.S173449] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
23 Tarancon-Diez L, De Pablo-Bernal RS, Jiménez JL, Álvarez-Ríos AI, Genebat M, Rosado-Sánchez I, Muñoz-Fernández MÁ, Ruiz-Mateos E, Leal M. Role of toll-like receptor 4 Asp299Gly polymorphism in the development of cardiovascular diseases in HIV-infected patients. AIDS 2018;32:1035-41. [PMID: 29547441 DOI: 10.1097/QAD.0000000000001797] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Zhang A, Wang J, Jing Q. Role of Folic Acid Drugs in the Treatment with Antithrombotic and Anticoagulant Drugs for Patients with Cardiovascular Diseases Based on the Analysis of Virtual Reality Medical Data. J Healthc Eng 2021;2021:9914787. [PMID: 34394899 DOI: 10.1155/2021/9914787] [Reference Citation Analysis]
25 Kronfli N, Bhatnagar SR, Hull MW, Moodie EEM, Cox J, Walmsley S, Gill J, Cooper C, Martel-Laferrière V, Pick N, Klein MB; Canadian Co-Infection Cohort Investigators. Trends in cause-specific mortality in HIV-hepatitis C coinfection following hepatitis C treatment scale-up. AIDS 2019;33:1013-22. [PMID: 30946155 DOI: 10.1097/QAD.0000000000002156] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
26 Butt ZA, Shrestha N, Wong S, Kuo M, Gesink D, Gilbert M, Wong J, Yu A, Alvarez M, Samji H, Buxton JA, Johnston JC, Cook VJ, Roth D, Consolacion T, Murti M, Hottes TS, Ogilvie G, Balshaw R, Tyndall MW, Krajden M, Janjua NZ; BC Hepatitis Testers Cohort. A syndemic approach to assess the effect of substance use and social disparities on the evolution of HIV/HCV infections in British Columbia. PLoS One 2017;12:e0183609. [PMID: 28829824 DOI: 10.1371/journal.pone.0183609] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
27 Jain A, Kolvekar T, Nair DR. HIV infection and lipids. Curr Opin Cardiol 2018;33:429-35. [PMID: 29601329 DOI: 10.1097/HCO.0000000000000520] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
28 Lee KK, Stelzle D, Bing R, Anwar M, Strachan F, Bashir S, Newby DE, Shah JS, Chung MH, Bloomfield GS, Longenecker CT, Bagchi S, Kottilil S, Blach S, Razavi H, Mills PR, Mills NL, McAllister DA, Shah ASV. Global burden of atherosclerotic cardiovascular disease in people with hepatitis C virus infection: a systematic review, meta-analysis, and modelling study. Lancet Gastroenterol Hepatol 2019;4:794-804. [PMID: 31377134 DOI: 10.1016/S2468-1253(19)30227-4] [Cited by in Crossref: 29] [Cited by in F6Publishing: 15] [Article Influence: 9.7] [Reference Citation Analysis]
29 Psichogiou M, Kapelios CJ, Konstantonis G, Argyris A, Nasothimiou E, Papadopoulou M, Kitas G, Papaioannou TG, Daikos GL, Sfikakis PP, Protogerou AD. Prevalence, Incidence, and Contributors of Subclinical Atheromatosis, Arteriosclerosis, and Arterial Hypertrophy in HIV-Infected Individuals: A Single-Center, 3-Year Prospective Study. Angiology 2019;70:448-57. [PMID: 30235944 DOI: 10.1177/0003319718801093] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
30 Lv L, Li Y, Fan X, Xie Z, Liang H, Shen T. HCV coinfection aggravated the decrease of platelet counts, but not mean platelet volume in chronic HIV-infected patients. Sci Rep 2018;8:17497. [PMID: 30504858 DOI: 10.1038/s41598-018-35705-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
31 Klein MB, Rockstroh JK, Wittkop L. Effect of coinfection with hepatitis C virus on survival of individuals with HIV-1 infection. Curr Opin HIV AIDS. 2016;11:521-526. [PMID: 27716732 DOI: 10.1097/coh.0000000000000292] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 3.4] [Reference Citation Analysis]
32 Meissner EG. Update in HIV-hepatitis C virus coinfection in the direct acting antiviral era. Curr Opin Gastroenterol 2017;33:120-7. [PMID: 28234770 DOI: 10.1097/MOG.0000000000000347] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
33 Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-jones D, Lopez-pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC, Sperling L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Journal of the American College of Cardiology 2019;73:e285-350. [DOI: 10.1016/j.jacc.2018.11.003] [Cited by in Crossref: 688] [Cited by in F6Publishing: 600] [Article Influence: 229.3] [Reference Citation Analysis]
34 Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019;73:3168-209. [PMID: 30423391 DOI: 10.1016/j.jacc.2018.11.002] [Cited by in Crossref: 433] [Cited by in F6Publishing: 430] [Article Influence: 108.3] [Reference Citation Analysis]
35 Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019;139:e1046-81. [PMID: 30565953 DOI: 10.1161/CIR.0000000000000624] [Cited by in Crossref: 39] [Cited by in F6Publishing: 46] [Article Influence: 9.8] [Reference Citation Analysis]
36 Costiniuk CT, Brunet L, Rollet-Kurhajec KC, Cooper CL, Walmsley SL, Gill MJ, Martel-Laferriere V, Klein MB. Tobacco Smoking Is Not Associated With Accelerated Liver Disease in Human Immunodeficiency Virus-Hepatitis C Coinfection: A Longitudinal Cohort Analysis. Open Forum Infect Dis 2016;3:ofw050. [PMID: 27047987 DOI: 10.1093/ofid/ofw050] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
37 Osibogun O, Ogunmoroti O, Michos ED, Spatz ES, Olubajo B, Nasir K, Maziak W. A systematic review of the associations between HIV/HCV coinfection and biomarkers of cardiovascular disease. Rev Med Virol 2018;28. [PMID: 29135056 DOI: 10.1002/rmv.1953] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
38 Lonardo A, Ballestri S, Guaraldi G, Nascimbeni F, Romagnoli D, Zona S, Targher G. Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV. World J Gastroenterol 2016; 22(44): 9674-9693 [PMID: 27956792 DOI: 10.3748/wjg.v22.i44.9674] [Cited by in CrossRef: 70] [Cited by in F6Publishing: 63] [Article Influence: 11.7] [Reference Citation Analysis]
39 Murala S, Nagarajan E, Bollu PC. Infectious Causes of Stroke. J Stroke Cerebrovasc Dis 2022;31:106274. [PMID: 35093633 DOI: 10.1016/j.jstrokecerebrovasdis.2021.106274] [Reference Citation Analysis]
40 Vachiat A, Mccutcheon K, Tsabedze N, Zachariah D, Manga P. HIV and Ischemic Heart Disease. Journal of the American College of Cardiology 2017;69:73-82. [DOI: 10.1016/j.jacc.2016.09.979] [Cited by in Crossref: 62] [Cited by in F6Publishing: 58] [Article Influence: 12.4] [Reference Citation Analysis]
41 Quiros-Roldan E, Raffetti E, Focà E, Brianese N, Ferraresi A, Paraninfo G, Pezzoli MC, Bonito A, Magoni M, Scarcella C, Castelli F. Incidence of cardiovascular events in HIV-positive patients compared to general population over the last decade: a population-based study from 2000 to 2012. AIDS Care 2016;28:1551-8. [PMID: 27321070 DOI: 10.1080/09540121.2016.1198750] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
42 Genebat M, Tarancón-Díez L, Pulido I, Álvarez-Ríos AI, Muñoz-Fernández MÁ, Ruiz-Mateos E, Leal M. Hepatitis C virus and cumulative infections are associated with atherogenic cardiovascular events in HIV-infected subjects. Antiviral Res 2019;169:104527. [PMID: 31158414 DOI: 10.1016/j.antiviral.2019.05.016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
43 Agarwala A, Liu J, Ballantyne CM, Virani SS. The Use of Risk Enhancing Factors to Personalize ASCVD Risk Assessment: Evidence and Recommendations from the 2018 AHA/ACC Multi-society Cholesterol Guidelines. Curr Cardiovasc Risk Rep 2019;13:18. [PMID: 32864034 DOI: 10.1007/s12170-019-0616-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Dold L, Schwarze-Zander C, Boesecke C, Mohr R, Langhans B, Wasmuth JC, Strassburg CP, Rockstroh JK, Spengler U. Survival of HIV/HCV co-infected patients before introduction of HCV direct acting antivirals (DAA). Sci Rep 2019;9:12502. [PMID: 31467319 DOI: 10.1038/s41598-019-48756-3] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
45 Boulougoura A, Sereti I. HIV infection and immune activation: the role of coinfections. Curr Opin HIV AIDS 2016;11:191-200. [PMID: 26720550 DOI: 10.1097/COH.0000000000000241] [Cited by in Crossref: 51] [Cited by in F6Publishing: 28] [Article Influence: 8.5] [Reference Citation Analysis]
46 Lacey A, Savinelli S, Barco EA, Macken A, Cotter AG, Sheehan G, Lambert JS, Muldoon E, Feeney E, Mallon PW, Tinago W; UCD ID Cohort Study. Investigating the effect of antiretroviral switch to tenofovir alafenamide on lipid profiles in people living with HIV. AIDS 2020;34:1161-70. [PMID: 32310899 DOI: 10.1097/QAD.0000000000002541] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 9.5] [Reference Citation Analysis]